Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561555 | 0.89 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL560730 | 0.87 | PIK3CD (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL562074 | 0.82 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL560770 | 0.80 | PIK3CA (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL561513 | 0.75 | GRM2 (0.43) | PIK3CA | |
| SCHEMBL561236 | 0.74 | PIK3CA (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL560725 | 0.73 | PIK3CA (0.71) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL561715 | 0.72 | PIK3CA (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL2883090 | 0.69 | KCNH2 (0.55) | KCNH2PTGS1PTGS2 | |
| SCHEMBL1688213 | 0.64 | KCNH2 (0.56) | KCNH2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | claimed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | claimed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | claimed |
| EP-2356117-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| WO-2012156379-A1 | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING | Universität Zürich (CH) | 2012-11-22 | — | — | WO | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| WO-2010059788-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.